Table 2.
Baseline characteristics of included studies
| Trials providing information | Intervention | No· Analysed (Intervention) | Trials providing information | Usual Care | No Analysed (Usual Care) | |
|---|---|---|---|---|---|---|
| Age-years (SD) | 377 | 58.6(8.3) | 8826 | 351 | 58.7(8.5) | 6247 |
| Male sex- n(%) | 319 | 5401 (63.7) | 8485 | 278 | 4262(62.2) | 6852 |
| Female sex-n(%) | 319 | 3084(36.3) | 8485 | 278 | 2590(37.8) | 6852 |
| BMI | 162 | 28.7(5.4) | 3335 | 144 | 29.2(6.5) | 2527 |
| Baseline Medications n(%) | ||||||
| Anti-hypertensive drugs(not classified) | 35 | 709(73.5) | 965 | 24 | 545(69.7) | 782 |
| Beta-Blockers | 144 | 2457(64.2) | 3830 | 123 | 2006(66.1) | 3034 |
| Diuretics | 111 | 1902(61.6) | 3086 | 93 | 1522(62.0) | 2453 |
| ACEI | 140 | 2769 (77.2) | 3589 | 120 | 2201(81.5) | 2698 |
| Calcium Channel Blockers | 51 | 405(26.1) | 1551 | 40 | 337(26.7) | 1262 |
| Nitrates | 39 | 468(44.4) | 1055 | 35 | 412(47.5) | 868 |
| ARB | 19 | 174(31.2) | 557 | 17 | 166(34.9) | 476 |
| Digitalis | 20 | 174(41.6) | 308 | 19 | 157(56.5) | 278 |
| Diagoxin | 34 | 359(44.5) | 806 | 32 | 349(46.4) | 752 |
| Aspirin (Anti-coagulant) | 40 | 947(87.8) | 1079 | 33 | 741(94.9) | 785 |
| Acetylsalycylic acid | 7 | 136(98.5) | 138 | 6 | 143(93.4) | 153 |
| Lipid Lowering Drugs (Statin, fibrate, omega) | 79 | 1527(69.3) | 2203 | 60 | 1232(75.4) | 1634 |
| Glycaemic Control | ||||||
| Metformin | 28 | 577(61.6) | 937 | 21 | 411(55.6) | 739 |
| Insulin | 18 | 68(16.7) | 408 | 14 | 74(23.5) | 315 |
| Oral Hypoglycaemic Agents(OHA) | 44 | 771(78.1) | 987 | 36 | 563(77.5) | 726 |
| Insulin + OHA | 20 | 239(43.7) | 547 | 14 | 212(49.8) | 426 |
SD Standard Deviation, BMI Body Mass Index, ACEI Angiotensin-Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blockers